Back

First < Newer 921-940 of 4747 Older> Last

Latest Forum Topics / Clearbridge Last:0.002 --

Post Reply

Medical Stock - Strong Shareholders

Mystic_D_001
Member

20-Oct-2021 07:22

Mystic_D_001 About Contact Quote this Post!

x 0
x 0

Alert Admin

Collection this round at 121 to 125.
After this Round, should have a nice run. DYODD

Useful To Me Not Useful To Me

tedlim
Veteran

20-Oct-2021 07:20

tedlim About Contact Quote this Post!

x 0
x 0

Alert Admin

I dont think that one can go wrong with healthcare biz...Clearbridge looks cheap...pls do your own DD...

Pension, health costs to dwarf Covid debt legacy in long term, says OECD
TUE, OCT 19, 2021 - 5:34 PM
[PARIS] The costs of repaying debt raised to help households and businesses through the Covid-19 crisis will be dwarfed by those from long-term trends like funding pensions and health services as societies age, the OECD said in a report on Tuesday.

Examining the economic outlook out to 2060, the Organisation for Economic Cooperation and Development said governments will increasingly have to contend with the costs associated with ageing populations and rising prices for public services.

That is on top of servicing the huge debts left by Covid-19, which will take decades to repay.

Many of the 38 mostly wealthy countries belonging to the Paris-based OECD saw their budget deficits blow out to record levels during the pandemic as they propped up their economies during lockdowns.

If current historically low interest rates persist, most OECD countries could afford to cover the extra strain on their budgets by adding to their debt piles, the report said.

But fiscal pressure on the median OECD country could reach 8 percentage points of GDP by 2060 as governments try to keep public service standards and benefits at current levels, the OECD calculated.

The increased strain on public finances was seen highest in Slovakia at 17 per cent, followed by Poland at 14 per cent, Spain and the Czech Republic at 13 per cent and France and Japan at 12 per cent.

But a permanent 1 percentage point increase in global interest rates from current historically low levels would raise fiscal pressure by as much as 1 per cent - 1.5 per cent in countries with the most debt, such as Greece, Italy and Japan, the OECD said.

To ease fiscal pressure there was little countries could do other than adopt reform packages to boost employment, which would in turn boost per capita GDP.

That could raise living standards by nearly 7 per cent by 2060 while those countries with the furthest to go down the path of reform - identified by the OECD as Belgium, France and Italy - could see gains of 9 per cent - 10 per cent.

Such packages would ease fiscal pressure by about 1.75 percentage points of GDP by 2060 in the median OECD country, the report estimated.

Useful To Me Not Useful To Me

TradeExpert
Veteran

19-Oct-2021 23:06

TradeExpert About Contact Quote this Post!

x 0
x 0

Alert Admin

Exactly

wehuattogether88 ( Date: 05-Oct-2021 12:56) Posted:

Everytime run out of ART test kits and also Good business for importing Sinovac.
No reason that Clearbridge price is still artificially low.

Useful To Me Not Useful To Me

shk363
Elite

18-Oct-2021 10:21

shk363 About Contact Quote this Post!

x 0
x 0

Alert Admin

cannot get at 120 anymore

Useful To Me Not Useful To Me

Mystic_D_001
Member

17-Oct-2021 19:39

Mystic_D_001 About Contact Quote this Post!

x 0
x 0

Alert Admin

Clearbridge should be in play from opening bell tomorrow.
It will lead Biolidics up too and possibly the medical counters too. Stay ready.

Joelton ( Date: 16-Oct-2021 11:18) Posted:

Clearbridge proposes new business unit to invest in and grow healthcare firms

PRECISION medicine firm Clearbridge Health is looking to enter the business of investing in and divesting healthcare companies.

It intends to seek shareholders' approval at an extraordinary general meeting to be convened.

The proposed new business will involve investments and injections of funds into entities in the global healthcare sector which are either Ebitda (earnings before interest, taxes, depreciation and amortisation) positive or " at an inflection point with a clear line of sight to profitability" , Clearbridge said.

Such portfolio companies may include medical technology (medtech) companies and pharmaceutical companies.

In a filing on Friday (Oct 15) night, Clearbridge said the " carefully deliberated investments" may take the form of equity, debt, a hybrid of both, or otherwise.

The group plans to then grow and develop these portfolio companies with a view to eventually exiting from them, be it through mergers and acquisitions, listings on public stock exchanges, trade sales, or other forms of divestments, in order to achieve positive returns.

" Portfolio companies that may have synergistic value may also be packaged together to achieve a collective divestment," it added.

To grow the portfolio companies' operations and business, Clearbridge intends to provide support including research and development, business development, market and commercialisation strategies, investment strategy, and financial planning.

The proposed business will form a new distinctive strategic business unit, separate from the current four reportable operating segments.

The existing core business segments comprise medical centres and clinics, healthcare systems such as renal care centres and clinical laboratories, and strategic medtech investments.

Currently, through its strategic medtech investments, the group gains access to new medical products and services.

Clearbridge said it remains committed to its existing business " as its continuity is in the best interest of the group" .

This foray into a new investment business is meant to create additional revenue streams, allow Clearbridge to better participate in the growth prospects of the healthcare sector, and enhance shareholder value.

The potential new unit will also enable Clearbridge to invest in entities that may be outside the scope of the existing segments.

Moreover, the group will be able to invest in the development of healthcare products such as diagnostic tests for endemic diseases, vaccines, pandemic-swabbing booths and digital healthcare. Clearbridge recently started supplying the Sinopharm Covid-19 vaccine in Singapore.

The proposed new business is substantially different from the existing business, and thus the expansion is expected to change the group' s existing risk profile, Clearbridge noted.

It will issue a circular to shareholders in due course, with further details on the proposed expansion.

Useful To Me Not Useful To Me

Joelton
Supreme

16-Oct-2021 11:18

Joelton About Contact Quote this Post!